743 related articles for article (PubMed ID: 18273835)
1. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
2. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Wierzbicki AS
Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
[TBL] [Abstract][Full Text] [Related]
3. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
4. Role for fibrate therapy in diabetes: evidence before FIELD.
Vergès B
Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
[TBL] [Abstract][Full Text] [Related]
5. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Jones PH
Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
7. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
Wierzbicki AS
Int J Clin Pract; 2006 Apr; 60(4):442-9. PubMed ID: 16620358
[TBL] [Abstract][Full Text] [Related]
8. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
Wierzbicki AS
Curr Opin Cardiol; 2009 Jul; 24(4):372-9. PubMed ID: 19424060
[TBL] [Abstract][Full Text] [Related]
9. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
Betteridge J
Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
[TBL] [Abstract][Full Text] [Related]
10. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
11. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Davidson M
Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
[TBL] [Abstract][Full Text] [Related]
12. Dyslipidaemia in diabetic patients: time for a rethink.
Shepherd J
Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
[TBL] [Abstract][Full Text] [Related]
13. Management of dyslipidemia in diabetes.
Solano MP; Goldberg RB
Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
[TBL] [Abstract][Full Text] [Related]
14. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.
Wierzbicki AS
Curr Opin Lipidol; 2010 Aug; 21(4):352-8. PubMed ID: 20625256
[TBL] [Abstract][Full Text] [Related]
15. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
16. What is the most effective strategy for managing diabetic dyslipidaemia?
Reasner CA
Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
[TBL] [Abstract][Full Text] [Related]
17. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
18. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
[TBL] [Abstract][Full Text] [Related]
19. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
Hobbs FD
Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
[TBL] [Abstract][Full Text] [Related]
20. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
